Journals / ANKEM Dergisi / 2012 / Cilt: 26 - Sayı: 3

Daptomycin susceptibility of Enterococcus spp. strains isolated from blood cultures

Kan kültürlerinden izole edilen enterokok suşlarının daptomisine duyarlılığı

Pages
111–115
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion all strains were found susceptible to daptomycin.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In recent years, resistant strains of Gram-positive bacteria have increased all over the world.
📊
Key Findings & Data:A total of 100 Enterococcus strains isolated from blood cultures in our laboratory were studied.
💡
Conclusion & Impact:In conclusion all strains were found susceptible to daptomycin.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In recent years, resistant strains of Gram-positive bacteria have increased all over the world. Problems in the treatment of multidrug resistant Gram-positive pathogens have created the need for more potent antibiotics. Daptomycin, effective in Gram-positive bacteria, is the first lipopeptide antibiotic used in human. The aim of this study was to investigate the daptomycin MIC values in vancomycin susceptible and resistant enterococci. A total of 100 Enterococcus strains isolated from blood cultures in our laboratory were studied. Daptomycin and van-comycin susceptibilities were investigated by E-test. Results were evaluated according to recommendations of Clinical and Laboratory Standards Institute. Of all isolates studied MIC range, MIC 50 and MIC 90 values were determined as 0.25-4 μg/ml, 1.5 μg/ml and 3 μg/ml, respectively. The MIC 50 and MIC 90 values of Enterococcus faecalis strains were found to be lower than the values of Enterococcus faecium strains. The MIC ranges, MIC 50 and MIC 90 values of vancomycin-resistant enterococci were significantly higher than vancomycin-susceptible strains. In conclusion all strains were found susceptible to daptomycin. This result showed that this antibiotic can be used safely in infections caused by enterococci.

Özet

Son yıllarda dirençli Gram-pozitif bakteriler tüm dünyada artmaya başlamıştır. Çoklu dirençli Gram pozitif patojenlerin tedavisindeki sorunlar, daha potent antibiyotiklere gerekliliği ortaya koymuştur. Daptomisin Gram pozitif bakterilere etkili olan, insanda kullanılan ilk lipopeptid antibiyotiktir. Bu çalışmanın amacı vankomisine duyarlı ve dirençli enterokoklarda daptomisin MİK değerlerinin araştırılmasıdır. Laboratuvarımızda kan kültürlerinden izole edilen toplam 100 enterokok suşu çalışmaya alınmıştır. Daptomisin ve vankomisin duyarlılığı E-test yöntemi ile çalışılmıştır. Sonuçlar Clinical and Laboratory Standards Institute önerilerine göre değerlendirilmiştir. Çalışılan tüm suşların MİK aralığı 0.25-4 μg/ml, MİK 50 değeri 1.5 μg/ml ve MİK 90 değeri 3 μg/ml olarak belirlenmiştir. Enterococcus faecalis suşlarının MİK 50 ve MİK 90 değerleri, Enterococcus faecium suşlarından daha düşük olarak saptanmıştır. Vankomisine dirençli enterokokların MİK aralıkları, MİK 50 ve MİK 90 değerleri vankomisine duyarlı suşlardan daha yüksek bulunmuştur. Sonuç olarak tüm suşların daptomisine duyarlı olduğu görülmüş ve bu antibiyotiğin enterokokların etken olduğu infeksiyonlarda güvenle kullanılabileceği düşünülmüştür.

🔖

Cite This Article

DAĞI, H. T., ARSLAN, U., UĞUR, A. R., ALP, F., FINDIK, D., TUNCER, İ. (2012). Daptomycin susceptibility of Enterococcus spp. strains isolated from blood cultures. ANKEM Dergisi, Cilt: 26 - Sayı: 3, 111–115. https://ajindex.com/articles/156756

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American Medical Centers, Antimicrob Agents Chemother 2001
  2. 45(6):1919-22. http://dx.doi.org/10.1128/AAC.45.6.1919- 1922.2001 PMid:11353654 PMCid:90574 2.Bell JM, Turnidge JD, Sader HS, Jones RN. Antimicrobial activity and spectrum of daptomy - cin: results from the surveillance program in Australia and New Zealand (2008), Pathology 2010
  3. 42(5):470-3. http://dx.doi.org/10.3109/00313025.2010.493869 PMid:20632825 3.Berzeg D, Kart Yaşar K, Şengöz G, Batı Kutlu S, Nazlıcan Ö. Klinik örneklerden izole edilen ente - rokok suşlarının antibiyotiklere duyarlılıkları, Türk Mikrobiyol Cem Derg 2005
  4. 35(4):279-83. 4.Carpenter CF, Chambers HF. Daptomycin: anot - her novel agent for treating infections due to drug-resistant gram-positive pathogens, Clin Infect Dis 2004
  5. 38(7):994-1000. http://dx.doi.org/10.1086/383472 PMid:15034832 5.Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing
  6. Twenty-First Informational Supplement, CLSI Document M100-S21, CLSI, Wayne (2011). 6.Çiçek-Şentürk G, Erdem İ, Yüksel S, Akın-Ertem S, Göktaş P. Enterokoklarda yüksek düzey aminogli - kozid direnci, Klimik Derg 2003
  7. 16(3):113-7. 7.Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A, Pignatari AC. Antimicrobial susceptibility of Gram-positive bacteria isolated in Brazilian hospi - tals participating in the SENTRY Program (2005- 2008), Braz J Infect Dis 2009
  8. 13(2):90-8. PMid:20140350 8.Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients, Pharmacotherapy 2009
  9. 29(7):792-9. http://dx.doi.org/10.1592/phco.29.7.792 PMid:19558253 9.Hızel K. Dirençli Gram pozitif kok infeksiyonları - nın tedavi ve yönetimi, ANKEM Derg 2011
  10. 25(Ek 2):50-3. 10.Kosmidis C, Levine DP. Daptomycin: pharmaco - logy and clinical use, Expert Opin Pharmacother 2010
  11. 11(4):615-25. http://dx.doi.org/10.1517/14656561003598893 PMid:20163272 11.Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant methicillin-resistant Staphylococcus aureus bacteremia, Clin Infect Dis 2005
  12. 40(7):1058-60. http://dx.doi.org/10.1086/428616 PMid:15825002 12.Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment of enterococcal bac - teraemia: results from the Cubicin Outcomes Registry and Experience (CORE), Int J Antimicrob Agents 2009